Published in Clin Cancer Res on January 15, 2004
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One (2007) 1.29
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Endothelin receptors as novel targets in tumor therapy. J Transl Med (2004) 1.07
Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer (2011) 1.06
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci (2011) 1.04
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer (2006) 0.99
Regulation of EP4 expression via the Sp-1 transcription factor: inhibition of expression by anti-cancer agents. Biochim Biophys Acta (2008) 0.90
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer (2006) 0.87
Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions. World J Gastroenterol (2006) 0.87
The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells. Cancer Prev Res (Phila) (2009) 0.84
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. J Clin Pathol (2006) 0.81
Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo. Int J Mol Sci (2010) 0.80
Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer. World J Gastroenterol (2010) 0.80
Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice. Exp Ther Med (2014) 0.78
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int (2014) 0.78
Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice. Oncol Lett (2012) 0.77
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One (2010) 3.38
Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA (2009) 2.85
Residual renal function at the start of dialysis and clinical outcomes. Nephrol Dial Transplant (2009) 2.69
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology (2002) 2.19
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res (2004) 2.17
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol (2005) 1.93
Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell (2008) 1.82
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst (2009) 1.80
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res (2010) 1.78
Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant (2009) 1.74
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 1.70
Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res (2006) 1.70
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res (2010) 1.69
Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer (2007) 1.67
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol (2004) 1.62
Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol (2006) 1.61
Self-reported smoking habits and serum cotinine levels in women with placental abruption. Acta Obstet Gynecol Scand (2010) 1.58
Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res (2003) 1.50
Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology (2006) 1.50
Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas (2006) 1.50
International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol (2006) 1.49
Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res (2007) 1.48
Employment of patients receiving maintenance dialysis and after kidney transplant: a cross-sectional study from Finland. Am J Kidney Dis (2011) 1.47
LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet (2008) 1.46
Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res (2005) 1.46
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Male fetal sex is associated with earlier onset of placental abruption. Acta Obstet Gynecol Scand (2010) 1.42
Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res (2007) 1.41
Abnormal cervical cytology is associated with increased nitric oxide release in the uterine cervix. Acta Obstet Gynecol Scand (2009) 1.40
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res (2010) 1.39
Intussusception and spontaneous amputation of the esophagus. J Thorac Cardiovasc Surg (2002) 1.38
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol (2002) 1.35
Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res (2005) 1.34
Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer (2007) 1.31
The novel WHO 2010 classification for gastrointestinal neuroendocrine tumours correlates well with the metastatic potential of rectal neuroendocrine tumours. Neuroendocrinology (2012) 1.29
Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Mod Pathol (2006) 1.27
Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet (2005) 1.26
Factors influencing the decision to start renal replacement therapy: results of a survey among European nephrologists. Am J Kidney Dis (2012) 1.26
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol (2004) 1.23
Identification of tumor epithelium and stroma in tissue microarrays using texture analysis. Diagn Pathol (2012) 1.23
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23
Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol (2003) 1.22
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst (2008) 1.22
Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet (2002) 1.21
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer (2011) 1.19
Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol (2002) 1.19
Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol (2003) 1.19
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer (2011) 1.18
Prognostic value of syndecan-1 expression in breast cancer. Oncology (2004) 1.16
Early-onset gastric carcinomas display molecular characteristics distinct from gastric carcinomas occurring at a later age. J Pathol (2004) 1.16
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res (2003) 1.14
Impact of fixative on recovery of mRNA from paraffin-embedded tissue. Diagn Mol Pathol (2004) 1.14
The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol (2010) 1.13
Updating on primary fallopian tube carcinoma. Acta Obstet Gynecol Scand (2007) 1.12
Gastric cancer: basic aspects. Helicobacter (2012) 1.11
A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res (2011) 1.10
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2011) 1.10